CN Patent

CN115246846B — 卢比替定新晶型及其制备

Assigned to Jiangsu Huiju Pharmaceutical Co ltd · Expires 2024-10-01 · 2y expired

What this patent protects

本发明涉及卢比替定新晶型C和新晶型D；晶型C的XRPD图谱在4.0°、7.8°、10.1°、11.9°、18.2°以及25.4°有特征布拉格角；晶型D的XRPD图谱在4.7°、7.9°、9.4°、11.9°、13.0°、16.8°、20.3°、24.6°以及25.5°有特征布拉格角。

USPTO Abstract

本发明涉及卢比替定新晶型C和新晶型D；晶型C的XRPD图谱在4.0°、7.8°、10.1°、11.9°、18.2°以及25.4°有特征布拉格角；晶型D的XRPD图谱在4.7°、7.9°、9.4°、11.9°、13.0°、16.8°、20.3°、24.6°以及25.5°有特征布拉格角。

Drugs covered by this patent

Patent Metadata

Patent number
CN115246846B
Jurisdiction
CN
Classification
—
Expires
2024-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Huiju Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.